TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 172 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.29 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $17,827 | -25.4% | 1,994,122 | +28.2% | 0.03% | -11.8% |
| Q2 2023 | $23,885 | -50.5% | 1,555,013 | -27.5% | 0.03% | -46.9% |
| Q1 2023 | $48,237 | +43.9% | 2,144,822 | +34.6% | 0.06% | +39.1% |
| Q4 2022 | $33,512 | -99.9% | 1,593,522 | +5.7% | 0.05% | -13.2% |
| Q3 2022 | $37,143,000 | -7.5% | 1,507,422 | -9.0% | 0.05% | +10.4% |
| Q2 2022 | $40,150,000 | +14.8% | 1,657,022 | +22.1% | 0.05% | +17.1% |
| Q1 2022 | $34,978,000 | +8.4% | 1,357,322 | +30.5% | 0.04% | +2.5% |
| Q4 2021 | $32,279,000 | +7.3% | 1,039,922 | -16.2% | 0.04% | +2.6% |
| Q3 2021 | $30,080,000 | +20.5% | 1,240,418 | -27.5% | 0.04% | +25.8% |
| Q2 2021 | $24,968,000 | -37.1% | 1,711,322 | +7.7% | 0.03% | -36.7% |
| Q1 2021 | $39,670,000 | -21.8% | 1,588,722 | -14.7% | 0.05% | -10.9% |
| Q4 2020 | $50,733,000 | – | 1,861,422 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |